We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
BELLUS Health Inc. has entered into a share purchase agreement with Taro Pharmaceuticals Inc. for the sale of BELLUS Health's wholly-owned subsidiary Thallion Pharmaceuticals Inc. including all the rights to the drug candidate ShigamabTM.